GKOS earnings call for the period ending March 31, 2020.
News & Analysis: Glaukos
Acquisition news was the culprit behind the hit to shares of the ophthalmic medical technology and pharmaceutical company.
Glaukos makes a bid for Avedro in an all-stock transaction.
Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.
Glaukos stock gets a boost from a competitor's failure.
Shares tumble after a Wall Street analyst cuts his rating. Here's what investors need to know.
Shares fall by double digits without any news. What's going on?
Management poured cold water on its financial projections for 2017, causes shares to take a step back.
Investors aren't too pleased with recent revisions to this year's sales expectations.
Outstanding sales growth wasn't enough to turn attention away from an unexpected loss in the second quarter.
Glaukos reported a banner year for its iStent glaucoma solution and gave investors plenty more to look forward to.